|
WO2020243464A1
|
|
Stable therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
|
|
CN111936159A
|
|
Treatment of hypoglycemia post bariatric surgery with micro-doses of stabilized glucagon
|
|
KR20200103029A
|
|
Treatment of exercise-induced hypoglycemia in type 1 diabetes and type 2 diabetes with insulin
|
|
CA3069533A1
|
|
Methods for treating congenital hyperinsulinism
|
|
AU2018275686A1
|
|
Precipitation resistant small molecule drug formulations
|
|
US2018271948A1
|
|
Methods for Producing Stable Therapeutic Glucagon Formulations in Aprotic Polar Solvents
|
|
EP3307295A1
|
|
Use of low dose glucagon
|
|
US2019083578A1
|
|
Use of low dose glucagon
|
|
WO2016196976A1
|
|
Glucagon delivery apparatuses and related methods
|
|
US2017087215A1
|
|
Methods for producing stable therapeutic formulations in aprotic polar solvents
|
|
AU2015215889A1
|
|
Intracutaneous injection
|
|
KR20170040330A
|
|
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
|
|
WO2015153728A1
|
|
Polar aprotic solvent-compatible infusion sets, components, and methods
|
|
EP3102184A2
|
|
Stable peptide formulations and methods for preparation
|
|
AU2014200476A1
|
|
Intracutaneous injection
|
|
US2014005135A1
|
|
Stable formulations for parenteral injection of small molecule drugs
|
|
US2014221288A1
|
|
Methods for rapidly treating severe hypoglycemia
|
|
AU2012332556A1
|
|
Formulations for the treatment of diabetes
|
|
KR20190090061A
|
|
Formulations for the treatment of diabetes
|
|
CN105853348A
|
|
Stable formulations for parenteral injection
|
